AbbVie (0QCV) Share Forecast & Price Target

Compare

11 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QCV Analyst Ratings

Moderate Buy

15 Buy

6 Hold

0 Sell

Based on 21 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QCV Stock 12 Month Forecast

Average Price Target

$238.61

▲(2.59% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $238.61 with a high forecast of $270.00 and a low forecast of $204.00. The average price target represents a 2.59% change from the last price of $232.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"172":"$172","271":"$271","196.75":"$196.8","221.5":"$221.5","246.25":"$246.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":238.61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$238.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$204.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[172,196.75,221.5,246.25,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.627,244.7326153846154,246.8382307692308,248.94384615384615,251.04946153846154,253.15507692307693,255.26069230769232,257.3663076923077,259.4719230769231,261.57753846153844,263.68315384615386,265.7887692307692,267.89438461538464,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.627,242.318,242.00900000000001,241.70000000000002,241.39100000000002,241.08200000000002,240.77300000000002,240.464,240.155,239.846,239.537,239.228,238.919,{"y":238.61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,242.627,239.6556923076923,236.68438461538463,233.71307692307693,230.74176923076925,227.77046153846155,224.79915384615384,221.82784615384617,218.85653846153846,215.88523076923076,212.91392307692308,209.94261538461538,206.9713076923077,{"y":204,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":191.728,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.767,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.291,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.933,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.063,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.619,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.494,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.081,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.071,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.627,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$270.00

Average Price Target$238.61

Lowest Price Target$204.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tim Anderson

Bank of America Securities

$220→$251

Hold

7.92%

Upside

Reiterated

10/03/25

AbbVie price target raised to $251 from $220 at BofAAbbVie price target raised to $251 from $220 at BofA

Rajesh Kumar

HSBC

$210→$225

Hold

-3.26%

Downside

Downgraded

10/01/25

AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC

Courtney Breen

Bernstein

―

Hold

―

Reiterated

09/30/25

Bernstein Reaffirms Their Hold Rating on AbbVie (ABBV)

David Risinger

Leerink Partners

$210→$243

Buy

4.48%

Upside

Reiterated

09/25/25

AbbVie (ABBV) Gets a Buy from Leerink PartnersLeerink Partners analyst Jeffrey La Rosa raised the price target on Abbvie (NYSE: ABBV) to $243.00 (from $210.00) while maintaining a Outperform rating.

Gavin Clark-Gartner

Evercore ISI

$207→$222

Buy

-4.55%

Downside

Reiterated

09/22/25

Evercore ISI Remains a Buy on AbbVie (ABBV)

David Amsellem

Piper Sandler

$231

Buy

-0.68%

Downside

Reiterated

09/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$170→$270

Buy

16.09%

Upside

Upgraded

09/17/25

Positive Report for AbbVie (ABBV) from Roth MKM

Terence Flynn

Morgan Stanley

$255

Buy

9.64%

Upside

Reiterated

09/16/25

AbbVie (ABBV) Gets a Buy from Morgan Stanley

Luisa Hector

Berenberg Bank

$170→$270

Buy

16.09%

Upside

Upgraded

09/16/25

AbbVie's Strategic Positioning and Growth Prospects Highlight Compelling Investment Opportunity

Chris Schott

J.P. Morgan

$200→$235

Buy

1.04%

Upside

Reiterated

09/16/25

AbbVie price target raised to $235 from $200 at JPMorganAbbVie price target raised to $235 from $200 at JPMorgan

Carter Gould

Cantor Fitzgerald

$215→$245

Buy

5.34%

Upside

Reiterated

09/15/25

AbbVie price target raised to $245 from $215 at Cantor FitzgeraldAbbVie price target raised to $245 from $215 at Cantor Fitzgerald

James Shin

Deutsche Bank

$173→$204

Hold

-12.29%

Downside

Reiterated

09/15/25

Deutsche Bank Sticks to Its Hold Rating for AbbVie (ABBV)

Vamil Divan

Guggenheim

$227

Buy

-2.40%

Downside

Reiterated

09/11/25

AbbVie (ABBV) Receives a Buy from Guggenheim

Mohit Bansal

Wells Fargo

$240→$260

Buy

11.79%

Upside

Reiterated

09/11/25

Wells sees AbbVie Rinvoq settlement being worth $11-$24 per shareWells sees AbbVie Rinvoq settlement being worth $11-$24 per share

Evan Seigerman

BMO Capital

$215→$240

Buy

3.19%

Upside

Reiterated

09/11/25

AbbVie price target raised to $240 from $215 at BMO CapitalAbbVie price target raised to $240 from $215 at BMO Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tim Anderson

Bank of America Securities

$220→$251

Hold

7.92%

Upside

Reiterated

10/03/25

AbbVie price target raised to $251 from $220 at BofAAbbVie price target raised to $251 from $220 at BofA

Rajesh Kumar

HSBC

$210→$225

Hold

-3.26%

Downside

Downgraded

10/01/25

AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC

Courtney Breen

Bernstein

―

Hold

―

Reiterated

09/30/25

Bernstein Reaffirms Their Hold Rating on AbbVie (ABBV)

David Risinger

Leerink Partners

$210→$243

Buy

4.48%

Upside

Reiterated

09/25/25

AbbVie (ABBV) Gets a Buy from Leerink PartnersLeerink Partners analyst Jeffrey La Rosa raised the price target on Abbvie (NYSE: ABBV) to $243.00 (from $210.00) while maintaining a Outperform rating.

Gavin Clark-Gartner

Evercore ISI

$207→$222

Buy

-4.55%

Downside

Reiterated

09/22/25

Evercore ISI Remains a Buy on AbbVie (ABBV)

David Amsellem

Piper Sandler

$231

Buy

-0.68%

Downside

Reiterated

09/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$170→$270

Buy

16.09%

Upside

Upgraded

09/17/25

Positive Report for AbbVie (ABBV) from Roth MKM

Terence Flynn

Morgan Stanley

$255

Buy

9.64%

Upside

Reiterated

09/16/25

AbbVie (ABBV) Gets a Buy from Morgan Stanley

Luisa Hector

Berenberg Bank

$170→$270

Buy

16.09%

Upside

Upgraded

09/16/25

AbbVie's Strategic Positioning and Growth Prospects Highlight Compelling Investment Opportunity

Chris Schott

J.P. Morgan

$200→$235

Buy

1.04%

Upside

Reiterated

09/16/25

AbbVie price target raised to $235 from $200 at JPMorganAbbVie price target raised to $235 from $200 at JPMorgan

Carter Gould

Cantor Fitzgerald

$215→$245

Buy

5.34%

Upside

Reiterated

09/15/25

AbbVie price target raised to $245 from $215 at Cantor FitzgeraldAbbVie price target raised to $245 from $215 at Cantor Fitzgerald

James Shin

Deutsche Bank

$173→$204

Hold

-12.29%

Downside

Reiterated

09/15/25

Deutsche Bank Sticks to Its Hold Rating for AbbVie (ABBV)

Vamil Divan

Guggenheim

$227

Buy

-2.40%

Downside

Reiterated

09/11/25

AbbVie (ABBV) Receives a Buy from Guggenheim

Mohit Bansal

Wells Fargo

$240→$260

Buy

11.79%

Upside

Reiterated

09/11/25

Wells sees AbbVie Rinvoq settlement being worth $11-$24 per shareWells sees AbbVie Rinvoq settlement being worth $11-$24 per share

Evan Seigerman

BMO Capital

$215→$240

Buy

3.19%

Upside

Reiterated

09/11/25

AbbVie price target raised to $240 from $215 at BMO CapitalAbbVie price target raised to $240 from $215 at BMO Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

11/14 ratings generated profit

Average Return

+4.83%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 78.57% of your transactions generating a profit, with an average return of +4.83% per trade.

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+10.31%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +10.31% per trade.

1 Year

Mohit BansalWells Fargo

Success Rate

23/23 ratings generated profit

Average Return

+22.53%

reiterated a buy rating 29 days ago

Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.53% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+44.40%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QCV Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QCV has received 25 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 0QCV average Analyst price target in the past 3 months is 238.61.

Each month's total comprises the sum of three months' worth of ratings.

0QCV Financial Forecast

0QCV Earnings Forecast

Next quarter’s earnings estimate for 0QCV is $3.27 with a range of $3.15 to $3.39. The previous quarter’s EPS was $2.97. 0QCV beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.

0QCV Sales Forecast

Next quarter’s sales forecast for 0QCV is $15.58B with a range of $15.38B to $15.98B. The previous quarter’s sales results were $15.42B. 0QCV beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.

0QCV Stock Forecast FAQ

What is GB:0QCV’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbvie’s 12-month average price target is 238.61.

What is GB:0QCV’s upside potential, based on the analysts’ average price target?

Abbvie has 2.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbvie a Buy, Sell or Hold?

Abbvie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.

What is Abbvie’s share price target?

The average share price target for Abbvie is 238.61. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $270.00 ,and the lowest forecast is $204.00. The average share price target represents 2.59% Increase from the current price of $232.58.

What do analysts say about Abbvie?

Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Abbvie?

To buy shares of GB:0QCV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (0QCV) Share Forecast & Price Target

0QCV Analyst Ratings

0QCV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

0QCV Analyst Recommendation Trends

0QCV Financial Forecast

0QCV Earnings Forecast

0QCV Sales Forecast

0QCV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts